RPC1063: reduction in MRI brain lesion activity after 24 weeks of treatment in patients with relapsing multiple sclerosis

The phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis ( RMS ) met the primary endpoint, reduction in MRI brain lesion activity. …

Multiple sclerosis: ATL1102, an antisense inhibitor of CD49d, reduces by 54.4% the cumulative number of new active brain lesions

Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes of the randomised, double-blind, placebo-controlled study in 77 …

Recombinant human interleukin 7 for treatment of progressive multifocal leukoencephalopathy

No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlying immunodeficiency. Researchers have described successful compassionate use of in a patient with …

Alemtuzumab: effect maintained in more than two-thirds of patients with relapsing-remitting multiple sclerosis at 4 years

Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis …

FDA ( Food and Drug Administration )–

Inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the product’s U.S. label

The FDA ( Food and Drug Administration ) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio ( Teriflunomide ) in the product’s U.S. lab …

Cell Therapy

Cells cultured from human placental tissue safe for patients with multiple sclerosis

Patients with multiple sclerosis were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published in the journal Multiple Sclerosis and Related Di …